title: Increased plasma fibronectin levels in patients with acute myocardial infarction complicated with left ventricular thrombus.
abstract: Fibronectin is a polymorphic and multifunctional glycoprotein that plays a wide-ranging role in hemostasis. In this study, it was aimed to determine plasma fibronectin levels and evaluate its possible role in left ventricular (LV) thrombus formation following acute myocardial infarction (AMI). We have determined clinical, echocardiographic, and biochemical parameters in 97 consecutive patients (aged 59 +/- 13; 87 men/10 women) with first anterior AMI. Two-dimensional echocardiography was performed on Days 1, 3, 7, 15, and 30. Blood samples were obtained within 24-48 h after the onset of symptoms. The study also included 30 healthy control subjects. Plasma fibronectin levels were significantly higher in patients with AMI than control subjects (38 +/- 13 vs. 25.2 +/- 8.7 mg/dl, P=.0001). LV thrombus was detected in 20 (20.6%) of 97 patients. Plasma fibronectin levels were significantly higher in patients with LV thrombus (Group 2) than in patients without LV thrombus (Group 1) (44.5 +/- 11 vs. 36.1 +/-13.4 mg/dl, P=.01). Although univariate analysis showed that plasma fibronectin levels were higher in patients with thrombus, multivariate analysis showed that plasma fibronectin levels were not an independent predictor of LV thrombus formation (P=.059). In multivariate analyses, only peak creatine phosphokinase (CPK) level and LV wall motion score index (WMSI) were independent predictors of thrombus formation (P=.007 and P=.0001, respectively). These results suggest the increased plasma fibronectin levels may be one of the risk factors for LV thrombus formation after AMI. However, further studies concerning the relation between plasma fibronectin levels and LV thrombus formation are necessary.
authors.affiliation: Department of Cardiology, Faculty of Medicine, Karadeniz Technical University, 61080 Trabzon, Turkey. corem71@yahoo.com
authors.forename: Cihan
authors.initials: C
authors.lastname: Orem
authors.forename: Sükrü
authors.initials: S
authors.lastname: Celik
authors.forename: Asim
authors.initials: A
authors.lastname: Orem
authors.forename: Mustafa
authors.initials: M
authors.lastname: Calapoğlu
authors.forename: Cevdet
authors.initials: C
authors.lastname: Erdöl
mesh_terms: D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D016022:Case-Control Studies; D003402:Creatine Kinase / Q000097:blood; D005260:Female; D005353:Fibronectins / Q000097:blood*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood* / Q000150:complications / Q000175:diagnosis; D011379:Prognosis; D012307:Risk Factors; D013927:Thrombosis / Q000097:blood / Q000000981:diagnostic imaging / Q000209:etiology*; D014463:Ultrasonography; D018487:Ventricular Dysfunction, Left / Q000097:blood / Q000000981:diagnostic imaging / Q000209:etiology*
chemical_list: D005353:Fibronectins; D003402:Creatine Kinase